Cyp3a13 recombinant protein product blog
Tags: Recombinant Protein; Cytochrome P450 3A13 (Cyp3a13); Cyp3a13 recombinant protein; Cyp3a13;
The Cyp3a13 cyp3a13 (Catalog #MBS9423516) is a Recombinant Protein produced from E Coli and is intended for research purposes only. The product is available for immediate purchase. The Recombinant Mouse Cytochrome P450 3A13 (Cyp3a13) reacts with Mouse and may cross-react with other species as described in the data sheet.The Cyp3a13 cyp3a13 product has the following accession number(s) (GI #6681115) (NCBI Accession #NP_031845.1) (Uniprot Accession #Q64464). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Our knowledge of the role of proteins in cellular processes is continually evolving. Most proteins, including Cytochrome P450 3A13 (Cyp3a13) are typically involved in one or more signaling pathways or biological processes. Professionally manufactured recombinant proteins are increasingly becoming essential and commonplace tools for elucidating new knowledge about the role of proteins in both health and disease.
Tag Info: N-terminal 6xHis-SUMO-tagged. Embryonic Tissue, Intestine, Kidney, Liver tissues are correlated with this protein. The following patways have been known to be associated with this gene. Cyp3a13 also interacts with the following gene(s): Cyp1a2, Cyp2b10, Cyp2c29, Cyp2c44, Cyp2e1. Drug-Induced Liver Injury, Drug-Related Side Effects and Adverse Reactions, Fibrosis, Inflammation, Kidney Diseases, Liver Cirrhosis, Liver Diseases, Necrosis, Poisoning, Weight Loss are some of the diseases may be linked to Recombinant Mouse Cytochrome P450 3A13 (Cyp3a13).